BRAF and colonic neoplasm: As anticipated, treatment with AUY922 resulted in marked reduction in activation of ERK and Akt in both wild-type (Lim1215 and Caco-2) and mutant (RKO and WiDr) BRAF colon cancer cells that was readily detectable at 16 hours (Figure 2A and 2B).